Exelixis' CELESTIAL Liver Trial Succeeds, But Can Cabozantinib Compete?

 
• By Emily Hayes
  
Generate a summary of this article
Listen to this article
Beta

CELESTIAL second-line liver cancer study is positive, but 4% response rate pales in comparison to PD-1 performance of Bristol's Opdivo and Merck's Keytruda.

Liver cancer, CT scan upper abdomen.

Exelixis Inc.'s data for its tyrosine kinase inhibitor cabozantinib in the Phase III CELESTIAL study of second-line-plus advanced hepatocellular cancer are positive, but raised some concerns about competitive prospects, particularly against Bristol-Myers Squibb Co.'s approved PD-1 inhibitor Opdivo and Merck & Co. Inc.'s Keytruda, which is also now poised for approval in this tumor type.

Currently, Bayer AG's tyrosine kinase inhibitor Nexavar (sorafenib) is the dominant treatment for advanced HCC and treatment options are...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D